I looked at the publication on PubMed: "Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement"
https://pubmed.ncbi.nlm.nih.gov/32955967/
It is free. The following COI statement is excerpted from the end of that publication. The authors affiliations with B&L and others is very encouraging. With the pipeline they should be able to partner without giving up shareholder value. I think the executive leadership is great.
Conflict of interest statement
K.J.M. has served as a consultant to Aldeyra Therapeutics, and is a co-inventor on a patent assigned to Aldeyra Therapeutics.
D.C. is an employee of and an investor in Aldeyra Therapeutics.
D.S.C. has received grants from Mallinckrodt; is a consultant for Aldeyra, Dompé, and Mallinckrodt; has received honoraria from AbbVie and Mallinckrodt; and has received travel reimbursement from AbbVie, Dompé, and Santen.
C.S.F. has received financial support from Aciont, Alcon, Aldeyra, Bausch & Lomb, Clearside, Biomedical, Dompé,, Eyegate Pharma, Mallinckrodt, Novartis, pSivida, and Santen; is an investor in Eyegate Pharma; is a consultant for Aldeyra, Allakos, Bausch & Lomb, Eyegate Pharma, Genentech, Novartis, and pSivida; and has received fees for lectures and services for speaker bureaus for Alcon, Allergan, and Mallinckrodt.
J.S. has received financial support for consultancy and research from Aldeyra, AbbVie, and Bausch & Lomb.
T.C.B. is an employee of Aldeyra Therapeutics and an investor in Novadigm Therapeutics, Springbank Pharmaceuticals, Evoke Pharma, and Aldeyra Therapeutics, and is an inventor on patents for Aldeyra Therapeutics.
Recent ALDX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease • Business Wire • 05/08/2024 11:00:00 AM
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 • Business Wire • 04/18/2024 11:00:00 AM
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease • Business Wire • 03/28/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 09:54:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:48:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/07/2024 09:40:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:06:42 PM
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 10:25:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:00:30 PM
- Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases • Business Wire • 01/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:05:14 PM
- Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis • Business Wire • 12/19/2023 12:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM